Clinical trial
A Randomized, Open-label, Multi-center Clinical Trial to Evaluate Addition of Peginterferon Alfa-2a to CHB Patients Treated With NAs and Achieved HBV DNA<15 IU/ml、HBeAg<100 PEIU/ml、HBsAg Positive and HBsAg<1500 IU/ml.
NCT02894918 is registered in ClinicalTrials.gov with Henan Provincial People's Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Open-label, Multi-center Clinical Trial to Evaluate Addition of Peginterferon Alfa-2a to CHB Patients Treated With NAs and Achieved HBV DNA<15 IU/ml、HBeAg<100 PEIU/ml、HBsAg Positive and HBsAg<1500 IU/ml.
- Lead sponsor
- Henan Provincial People's Hospital
- Phase
- Phase 4
- Overall status
- Unknown status
- Start date
- September 30, 2016
- Completion date
- December 31, 2018
- Enrollment
- 114 (estimated)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
chronic hepatitis b